Join the Pneumococcal Disease Prophylaxis group to help and get support from people like you.
Pneumococcal Disease Prophylaxis News
CDC Lowers Age for First Pneumococcal Vaccine to 50
THURSDAY, Oct. 24, 2024 – The recommended first age at which Americans should get the pneumococcal vaccine has been lowered from 65 to 50, the U.S. Centers for Disease Control and Prevention...
FDA Approves Capvaxive (pneumococcal 21-valent conjugate vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
RAHWAY, N.J.--(BUSINESS WIRE) June 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved...
U.S. FDA Approves Prevnar 20, Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for Infants and Children
NEW YORK--(BUSINESS WIRE) April 27, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Prevnar 20®(20-valent Pneumococcal Conjugate Vaccine) ...
U.S. FDA Approves Merck’s Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four-dose series and superior immune responses for important...
FDA Approves Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults
KENILWORTH, N.J.--(BUSINESS WIRE)-- (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved Vaxneuvance (Pneumococcal...
FDA Approves Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for Adults Ages 18 Years or Older
NEW YORK--(BUSINESS WIRE) June 08, 2021 – Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) f...
Pfizer Receives FDA Approval for Prevnar 13 in Adults Age 18 Through 49
July 12, 2016 - Pfizer Inc. (NYSE:PFE) today announced that Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. Food and Drug Administration (FDA) approval...
FDA Approves Prevnar 13 Pneumococcal Disease Vaccine
SILVER SPRING, Md., Feb. 24 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages...